INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Pharmacotherapy Of Migraine: Recent Advances and Future Perspectives

Pagar Nayana*, Pagar Aakanksha, Pagar Durgesh

Department of Pharmacology, Divine College of Pharmacy, Satana.

ARTICLE INFO

Published: 25 July 2026
Keywords:
Migraine, Headache, Pathophysiology, Treatment, Diagnosis, Therapy
DOI:
10.5281/zenodo.21562927

ABSTRACT

Migraine is a highly prevalent and disabling neurological disorder characterized by recurrent episodes of moderate-to-severe headache accompanied by nausea, vomiting, photophobia, and phonophobia. Advances in the understanding of migraine pathophysiology have shifted the concept of migraine from a purely vascular disorder to a complex neurovascular disease involving the trigeminovascular system, cortical spreading depression, neurogenic inflammation, and the release of calcitonin gene-related peptide (CGRP). Conventional pharmacological therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, ergot derivatives, beta-blockers, antiepileptics, antidepressants, and calcium channel blockers, continue to play important roles in the acute and preventive management of migraine. However, these therapies are often limited by inadequate efficacy, adverse effects, contraindications, and medication-overuse headache. Recent therapeutic advances have introduced mechanism-based treatments such as CGRP monoclonal antibodies, gepants, and ditans, which provide improved efficacy, better tolerability, and expanded treatment options, particularly for patients with cardiovascular comorbidities or treatment-resistant migraine. Emerging strategies including neuromodulation, biomarker-guided therapy, pharmacogenomics, artificial intelligence-assisted clinical decision-making, and novel molecular targets such as PACAP and transient receptor potential (TRP) channels are expected to further transform migraine management. This review summarizes the current understanding of migraine pathophysiology, classification, pharmacological treatment, recent therapeutic advances, and future perspectives, highlighting the transition toward personalized and precision-based approaches aimed at improving long-term clinical outcomes and quality of life.

INTRODUCTION

Migraine is a complex neurological disorder characterized by recurrent headache attacks with

***Corresponding Author:** Pagar Nayana
Address: *Department of Pharmacology, Divine College of Pharmacy, Satana.*
Email ✉: naynapagar02@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

variable intensity, duration, and associated symptoms. It is considered one of the leading causes of disability worldwide, affecting individuals across different age groups and significantly influencing physical, emotional, and social well-being. According to the World Health Organization, migraine is among the most disabling neurological conditions, contributing substantially to years lived with disability.Migraine attacks commonly present as unilateral, pulsating headaches that may last from several hours to days. Symptoms such as nausea, vomiting, photophobia, and phonophobia frequently accompany headache episodes. Some individuals experience migraine with aura, which involves reversible neurological symptoms including visual disturbances, sensory changes, or speech difficulties before or during an attack.The pathophysiology of migraine involves complex interactions between neuronal excitability, inflammation, vascular mechanisms, and neurotransmitter pathways. Activation of the trigeminovascular system and release of inflammatory neuropeptides, particularly calcitonin gene-related peptide (CGRP), play important roles in migraine development. Understanding these mechanisms has contributed to the discovery of novel therapeutic targets.Pharmacological management of migraine is broadly divided into acute and preventive approaches. Acute therapies aim to terminate or reduce the severity of an ongoing attack and include analgesics, NSAIDs, triptans, gepants, and ditans. Preventive therapies are recommended for patients with frequent or severe attacks and include beta-blockers, antiepileptic drugs, antidepressants, botulinum toxin type A, and newer CGRP-targeted agents.Despite significant progress, current migraine treatments have limitations, including incomplete effectiveness, medication overuse headache, tolerability issues, and lack of response in certain patient populations. Recent developments in migraine pharmacotherapy have focused on mechanism-based treatments designed to provide better efficacy and safety. The emergence of CGRP monoclonal antibodies and oral CGRP receptor antagonists represents a major advancement in migraine prevention and acute management. This review aims to summarize the existing pharmacological approaches for migraine treatment, evaluate recent therapeutic advances, and discuss future directions for improving individualized migraine care. Historically, migraine was considered primarily a vascular disorder caused by cerebral vasodilation. However, advances in neuroimaging, molecular neuroscience, and neuropharmacology have fundamentally changed this concept. Migraine is now recognized as a disorder of brain excitability involving activation of the trigeminovascular system, cortical spreading depression, neurogenic inflammation, and release of neuropeptides, particularly calcitonin gene-related peptide (CGRP). These discoveries have transformed therapeutic strategies by enabling the development of disease-specific drugs that directly target migraine pathophysiology rather than merely alleviating symptoms.[1,3,6]

Conventional pharmacotherapy has relied heavily on nonspecific medications originally developed for hypertension, epilepsy, or depression. Although effective in many patients, these therapies are associated with limitations such as delayed onset of preventive benefit, adverse drug reactions, contraindications, medication-overuse headache, and poor long-term adherence. The past decade has witnessed unprecedented progress in migraine therapeutics. The introduction of CGRP monoclonal antibodies has revolutionized preventive therapy by providing highly specific, long-acting agents with favorable tolerability. Similarly, orally active CGRP receptor antagonists (gepants) and the selective 5-HT1F agonist

lasmiditan have expanded treatment options for acute migraine, especially in patients who cannot use triptans because of cardiovascular disease. Emerging research is also focusing on pharmacogenomics, precision medicine, biomarkers, artificial intelligence-based prediction of migraine attacks, RNA-based therapeutics, gene editing technologies, microbiome modulation, and digital therapeutics. These innovations may further improve treatment personalization and clinical outcomes while minimizing adverse effects.[1,3,6]

TRIGGERS FOR MIGRAINE

Migraine attacks can be triggered by a variety of internal and external factors. These triggers include environmental conditions, certain foods, hormonal or physiological changes, and lifestyle-related influences that may activate the brain mechanisms involved in migraine. The importance and frequency of specific triggers can differ across regions because of variations in cultural, social, and environmental conditions. In India, research examining migraine triggers remains limited, highlighting the need for more studies in this area. A clear understanding of these triggering factors is essential for identifying individual risk factors, improving patient education, and developing effective strategies for migraine prevention and management.[10,13,16]

TABLE 1: Triggers For Migraine[10,13,16]

Environmental triggers	Odours, bright lights, noise, and other excessive sensory stimuli. Painful stimuli that trigger migraine usually occur in the head and neck. The most common of these are neck injury and spasm, temporomandibular joint pain, and sinus inflammation. 40% of migraineurs report that they are affected by weather changes.
Food triggers	Byproducts of food aging are found in fermented products like red wine, aged cheeses, and yeast in fresh bread and yogurt. Foods with chemicals similar to the neurotransmitters that our brains use are coffee, chocolate, MSG, and the nitrates used as preservatives in many of our prepackaged foods.
Physiologic triggers	Stress, fatigue, lack of sleep, or alter their sleep schedule, sleeping too much, hunger, exercise, pain, hormone changes, like the drop in estrogen levels before the menstrual period or after menopause.

CLASSIFICATION OF MIGRAINE (ICHD-3)[1]

The classification of migraine has been challenging because there are no specific biological or clinical markers that definitively identify the disorder. In addition, individuals may experience more than one migraine subtype or have both migraine and tension-type headache, making diagnosis more complex. The overlap of symptoms and the limited validity of some diagnostic criteria have also made it difficult to establish clear boundaries between migraine and other primary headache disorders. To address these challenges, the International Headache Society (IHS), through its Headache Classification Committee, developed standardized diagnostic criteria that define the different migraine subtypes and improve the consistency of diagnosis in both clinical practice and research.[8,9]

TABLE 2: Classification Of Migraine (Ichd-3)[8,9]

Type	Characteristics
Migraine without aura	Most common form; recurrent unilateral throbbing headache with nausea and sensitivity to light and sound
Migraine with aura	Transient neurological symptoms (usually visual) precede or accompany headache
Chronic migraine	≥15 headache days/month for >3 months, with migraine features on ≥8 days/month
Hemiplegic migraine	Migraine associated with reversible motor weakness
Vestibular migraine	Recurrent vertigo associated with migraine symptoms
Menstrual migraine	Migraine attacks temporally related to menstruation

NEUROBIOLOGY AND PATHOPHYSIOLOGY OF MIGRAINE[2]

Migraine is currently recognized as a complex neurovascular disorder involving abnormal neuronal excitability, dysfunction of the trigeminovascular system, release of inflammatory neuropeptides, altered sensory processing, and genetic susceptibility. Earlier concepts attributed migraine primarily to vascular changes; however, contemporary evidence demonstrates that neuronal activation precedes vascular alterations. The headache phase results from activation of nociceptive pathways, peripheral and central sensitization, and sustained neurotransmitter release.[2]

The pathophysiology of migraine involves interactions among the cerebral cortex, brainstem, hypothalamus, trigeminal ganglion, meningeal blood vessels, and higher cortical pain-processing centers. Several neurotransmitters and neuromodulators—including calcitonin gene-related peptide (CGRP), serotonin (5-HT), glutamate, dopamine, nitric oxide (NO), and pituitary adenylate cyclase-activating peptide (PACAP)—play central roles in initiating and sustaining migraine attacks. These discoveries have led to targeted therapies that interfere with specific molecular pathways.[4,5,6,8]

Genetic factors play an important role in determining an individual's susceptibility to migraine. Many people with migraine have a family history of the disorder, suggesting inherited influences on brain function. Genetic variations can affect ion channels, neurotransmitter systems, and mechanisms responsible for maintaining normal neuronal activity. These changes may increase the tendency of neurons to become overactive in response to internal or external stimuli. Rare inherited conditions, such as familial hemiplegic migraine, have been associated with mutations affecting calcium channels and other proteins involved in regulating nerve cell communication. These genetic alterations contribute to increased cortical excitability and make the nervous system more sensitive to migraine triggers. Several neurotransmitters influence the development and progression of migraine. Serotonin (5-hydroxytryptamine or 5-HT) plays an important role in regulating pain transmission and vascular responses. Abnormal serotonin activity can influence trigeminal nerve activation and contribute to migraine symptoms. This mechanism explains why medications such as triptans, which act on specific serotonin receptors, are effective in reducing migraine attacks.[4,5,6,8]

PATHOPHYSIOLOGY OF MIGRAINE [1,3]



TABLE 3. Major Neurotransmitters in Migraine[2]

Neurotransmitter	Primary Action	Pharmacological Target
CGRP	Vasodilation, pain transmission	Monoclonal antibodies, gepants
Serotonin	Inhibits CGRP release	Triptans, ditans
Glutamate	Cortical spreading depression	Topiramate
Nitric oxide	Vasodilation	Experimental NOS inhibitors
Dopamine	Nausea, premonitory symptoms	Dopamine antagonists
Substance P	Neurogenic inflammation	Investigational target
PACAP	Trigeminal activation	PAC1 antagonists (under investigation)

TABLE 4. Major Pharmacological Targets in Migraine[8]

Target	Physiological Role	Representative Drugs
5-HT1B receptor	Cranial vasoconstriction, inhibition of CGRP release	Sumatriptan, Rizatriptan
5-HT1D receptor	Inhibits neuropeptide release	Triptans
5-HT1F receptor	Reduces neuronal excitability without vasoconstriction	Lasmiditan
CGRP receptor	Pain transmission, vasodilation	Erenumab, Ubrogepant
CGRP ligand	Neurogenic inflammation	Fremanezumab, Galcanezumab, Eptinezumab

TABLE 5 . Pharmacological treatment of migraine based on therapeutic target[16,18]

Therapeutic Target	Drug Class	Representative Drugs	Mechanism of Action	Clinical Use	Limitations
Pain and inflammation	NSAIDs	Ibuprofen, Naproxen, Diclofenac	Inhibit COX-1/COX-2 enzymes, reducing prostaglandin synthesis	First-line treatment for mild-to-moderate migraine	Gastrointestinal irritation, renal toxicity, medication-overuse headache
Central pain modulation	Analgesics	Paracetamol (Acetaminophen)	Inhibits central prostaglandin synthesis	Mild migraine or combination therapy	Limited efficacy in severe attacks; hepatotoxicity in overdose
Serotonin (5-HT1B/1D) receptors	Triptans	Sumatriptan, Zolmitriptan, Rizatriptan, Eletriptan	Cranial vasoconstriction and inhibition of CGRP release	Moderate-to-severe acute migraine	Contraindicated in patients with cardiovascular disease
Serotonin (5-HT1F) receptors	Ditans	Lasmiditan	Inhibits trigeminal pain pathways without vasoconstriction	Acute migraine in patients with cardiovascular risk	Dizziness, sedation, driving restrictions after use
CGRP receptor	Gepants	Ubrogepant, Rimegepant, Atogepant, Zavegepant	Block CGRP receptor-mediated nociceptive signaling	Acute treatment and preventive therapy	Cost and limited long-term clinical experience
CGRP ligand/receptor	Monoclonal antibodies	Erenumab, Fremanezumab, Galcanezumab, Eptinezumab	Neutralize CGRP signaling to prevent migraine attacks	Prevention of episodic and chronic migraine	High cost, injectable administration

RECENT ADVANCES IN PHARMACOTHERAPY OF MIGRAINE[06,3]

The therapeutic landscape of migraine has undergone significant transformation over the last decade due to improved understanding of migraine neurobiology. Earlier pharmacological approaches mainly focused on symptomatic relief using nonsteroidal anti-inflammatory drugs (NSAIDs), ergot derivatives, and serotonin receptor agonists (triptans). However, these therapies are associated with limitations including inadequate response, recurrence of headache, medication-overuse headache, and contraindications in patients with cardiovascular disorders.[6]

The identification of the trigeminovascular pathway and the discovery of calcitonin gene-related peptide (CGRP) as a key mediator of migraine pathogenesis have resulted in the development of mechanism-based therapies. Recent advances include CGRP monoclonal antibodies, small molecule CGRP receptor antagonists (gepants), selective serotonin 5-HT1F receptor agonists (ditans), neuromodulation approaches, and emerging molecular targets such as PACAP and TRP channels.[6,3]

These newer therapies provide improved efficacy, better tolerability, and reduced cardiovascular risks compared with traditional medications. Current research is focused on precision medicine, pharmacogenomics, artificial intelligence-based treatment selection, and novel biological targets for individualized migraine management.

Recent advances in migraine management have shifted from conventional therapies such as antiepileptics and triptans toward targeted therapies, including calcitonin gene-related peptide (CGRP)-based treatments, selective serotonin receptor agonists, neuromodulation devices, and personalized medicine. These novel approaches aim to improve efficacy, reduce adverse effects, and provide better outcomes for patients with both episodic and chronic migraine.[3]

TABLE 5. Recent Advances In Pharmacotherapy Of Migraine[18]

Sr. No.	Recent Advances	Mechanism of Action	Key Findings	Current Status
1	CGRP monoclonal antibodies (Erenumab, Fremanezumab, Galcanezumab, Eptinezumab)	Block calcitonin gene-related peptide (CGRP) pathway involved in migraine pathophysiology	Significantly reduce monthly migraine days with good long-term tolerability	FDA-approved for migraine prevention
2	Gepants (Ubrogepant, Rimegepant, Atogepant, Zavegepant)	Oral CGRP receptor antagonists	Effective in acute treatment and prevention of migraine with fewer cardiovascular concerns than triptans	Approved for acute and/or preventive treatment
3	Ditans (Lasmiditan)	Selective 5-HT1F receptor agonist	Effective for acute migraine without vasoconstriction; suitable for patients with cardiovascular disease	FDA-approved for acute migraine
4	Neuromodulation	Non-invasive stimulation of trigeminal or vagus nerves	Provides pain relief with minimal adverse effects in selected patients	Increasing clinical use
5	Personalized Medicine	Biomarker-guided therapy and individualized treatment	Improves treatment selection and reduces trial-and-error prescribing	Emerging approach
6	Artificial Intelligence	Machine learning for diagnosis and prediction of migraine attacks	Enhances diagnostic accuracy and supports personalized management	Under research and early clinical application

FUTURE PROSPECTS OF MIGRAINE PHARMACOLOGY[17]

Migraine pharmacology is rapidly evolving from non-specific symptomatic treatments toward targeted, personalized therapies. Advances in understanding migraine pathophysiology, particularly the role of calcitonin gene-related peptide (CGRP), neuroinflammation, and genetic factors, are driving the development of safer and more effective medications. The following areas represent the major future prospects in migraine pharmacology.[17]

TABLE 6. Future Prospects Of Migraine Pharmacology[17]

Future Direction	Description	Potential Impact
Next-generation CGRP therapies	Development of longer-acting CGRP monoclonal antibodies and oral CGRP receptor antagonists with improved efficacy and safety.	Better long-term prevention with fewer adverse effects and improved patient adherence.
Novel molecular targets	Investigation of PACAP, PAC1 receptor antagonists, orexin receptors, nitric oxide pathways, glutamate receptors, and ion channels.	New treatment options for patients who do not respond to current therapies.
Combination therapy	Combining CGRP-targeted drugs with conventional preventive agents or neuromodulation.	Enhanced efficacy and reduced migraine frequency in refractory patients.
Neuromodulation-assisted pharmacotherapy	Integration of non-invasive neuromodulation devices with pharmacological treatment.	Reduced medication dependence and improved quality of life.
Improved drug delivery systems	Development of nasal sprays, transdermal patches, sustained-release formulations, nanoparticles, and microneedle systems.	Faster onset of action, improved bioavailability, and greater patient convenience.
Neuroinflammation-targeted therapies	Drugs targeting inflammatory cytokines, microglial activation, and oxidative stress.	Disease-modifying therapies that may prevent migraine progression.
Digital health integration	Wearable devices and smartphone applications to monitor symptoms, triggers, medication use, and treatment response.	Improved adherence and real-time disease management.
Preventive therapies for chronic migraine	Development of safer long-term preventive medications with minimal cardiovascular and neurological adverse effects.	Reduced disability and improved long-term patient outcomes.

CONCLUSION

Migraine is a complex neurological disorder that contributes significantly to disability and reduced quality of life worldwide. Advances in the understanding of migraine mechanisms, particularly the role of the trigeminovascular system and CGRP pathway, have transformed treatment strategies from nonspecific symptom control to targeted pharmacological approaches. Conventional therapies such as NSAIDs, triptans, beta-blockers, antiepileptics, and antidepressants remain useful; however, limitations related to adverse effects, contraindications, and variable treatment response highlight the need for improved options. The development of CGRP monoclonal antibodies, gepants, and ditans has marked a major advancement in migraine

management by providing effective and better-tolerated therapies for acute and preventive treatment. Emerging approaches, including neuromodulation, novel molecular targets, and combination therapies, may further benefit patients with refractory migraine. Future research focusing on precision medicine, pharmacogenomics, biomarkers, artificial intelligence, and innovative drug delivery systems is expected to support individualized treatment selection and optimize therapeutic outcomes.

Overall, the continuous evolution of migraine pharmacotherapy offers promising opportunities to reduce disease burden, improve treatment adherence, and enhance the quality of life of individuals affected by migraine. Further clinical studies and improved accessibility of advanced therapies will be essential for achieving more effective and personalized migraine care.

AKNOWLEGDEMENT

The authors express their sincere appreciation to all researchers, scientists and experts whose working has provided to the development of this review article on creams. We would like to extend our special thanks to our project guide Mr. Durgesh S. Pagar Sir for providing us with the necessary resources and support to complete this review

REFERENCES

1. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. *Physiol Rev*. 2017;97(2):553-622.
2. Charles A. The pathophysiology of migraine: implications for clinical management. *Lancet Neurol*. 2018;17(2):174-182.
3. Dodick DW. A phase-by-phase review of migraine pathophysiology. *Headache*. 2018;58(Suppl 1):4-16.
4. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211.
5. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. *J Neurosci*. 2015;35(17):6619-6629.
6. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol*. 1999;61:153-180.
7. Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. *Headache*. 2007;47(Suppl 1):S17-S25.
8. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. *Annu Rev Pharmacol Toxicol*. 2015;55:533-552.
9. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007;68(5):343-349.
10. Kelman L. The triggers or precipitants of the acute migraine attack. *Cephalalgia*. 2007;27(5):394-402.
11. Wöber C, Holzhammer J, Zeitlhofer J, Wessely P, Wöber-Bingöl C. Trigger factors of migraine and tension-type headache. *Cephalalgia*. 2006;26(2):133-139.
12. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine: classification, characteristics and treatment. *Nat Rev Neurol*. 2012;8(3):162-171.
13. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. *Curr Pain Headache Rep*. 2012;16(1):86-92.

14. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. *Nat Rev Neurol*. 2016;12(8):455-464.
15. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment. *Headache*. 2015;55(1):3-20.
16. Silberstein SD. Preventive migraine treatment. *Neurology*. 2000;55(4):754-763.
17. Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: a new era in migraine prevention. *Headache*. 2018;58(1):238-250.
18. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: integrated approaches to clinical management and future directions. *Lancet*. 2021;397(10283):1505-1518.

HOW TO CITE: Pagar Nayana, Pagar Aakanksha, Pagar Durgesh, Pharmacotherapy Of Migraine: Recent Advances and Future Perspectives, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 7, 4890-4899, https://doi.org/10.5281/zenodo.21562927